Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001306923-25-000009
Filing Date
2025-02-13
Accepted
2025-02-13 16:02:42
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10409
2 exhibitajointfilingagreement.htm EX-99 4204
  Complete submission text file 0001306923-25-000009.txt   16406
Mailing Address 470 UNIVERSITY AVE PALO ALTO CA 94301
Business Address 470 UNIVERSITY AVE PALO ALTO CA 94301 650-325-0772
Palo Alto Investors LP (Filed by) CIK: 0001306923 (see all company filings)

EIN.: 770558164 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Subject) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88023 | Film No.: 25620044
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)